Philadelphia International Medicine

07/05/2022

We regret to inform you that PIM will cease operations effective July 31, 2022 due to the impact of the COVID-19 pandemic and changing in healthcare environment.

For over 20 years Philadelphia International Medicine has connected world-renowned Philadelphia-area medical centers to countless patients and partners across the globe. We thank you for your commitment to and partnership with Philadelphia International Medicine.

Although the organization will be dissolving, please rest assured that there will be no disruption or change in the top quality care being provided to current or future international patients. Our owners (Temple Health – Temple University Health System and Thomas Jefferson University Hospitals) are committed to developing a seamless transition and continuing to partner with your organization to provide these invaluable services to the international community.

Temple Health Jefferson Health

12/31/2021

Philadelphia International Medicine wishes you and yours a happy and healthy new year. We look forward to continuing to strive towards excellence in international healthcare in 2022 with our world-renowned network, forward-thinking team and innovative partners. Happy New Year!

12/22/2021

As we approach the holiday season, we have so much to be thankful for. We feel lucky and honored to serve, collaborate, and work with you to advance excellence in international healthcare. Happy Holidays from the Philadelphia International Medicine team!

12/10/2021

Dr. Enrique Hernandez specializes in comprehensive, compassionate care of women with gynecologic cancer and pre-cancerous conditions, using the most up-to-date and sophisticated diagnostic and treatment tools. His research in gynecologic oncology has produced two books and over 145 articles. Dr. Hernandez is the recipient of many awards including: Philadelphia Magazine's Top Doctors 1991-2021, U.S. News & World Report Best Doctors and Citizen of the Year Award. Dr. Hernandez is an active member of American College of Surgeons, College of Physicians of Philadelphia and American Cancer Society.


Temple Health

12/08/2021

Dr. Kelly is known nationally for his research on urological malignancies and his expertise in drug design and development.

“One of our dilemmas now is how to choose the right treatment for the right patient at the right time,” says Kelly, who joined Jefferson in 2010 as director of the Division of Solid Tumor Oncology in the Department of Medical Oncology and associate director of translational research at the Kimmel Cancer Center.

Kelly’s research linking elevated prostate-specific antigen levels to prostate cancer treatment outcomes remains a foundation for drug development in patients with advanced prostate cancer today. More recently, he has been instrumental in developing multiple compounds such as microtubule disrupting agents, histone deacetylase (HDAC) inhibitors and anti-angiogenesis therapies for urologic cancers. He has successfully developed several new drugs from bench through clinical trial and approval – most notably the HDAC-inhibitor, vorinostat, marketed by Merck as Zolinza and approved for cutaneous T-cell lymphoma.

Prior to joining the Jefferson faculty, Kelly directed the solid tumor clinical investigative program at Yale University’s School of Medicine, where he also co-directed prostate and urological oncology. He spent the previous 15 years on the faculty at Memorial-Sloan Kettering Cancer Center. He currently serves on the editorial boards of Clinical Prostate Cancer, Journal of Clinical Oncology, and Nature Clinical Practice Oncology.


Jefferson Health

11/25/2021

Wishing you and yours a happy thanksgiving!

11/24/2021

Proud to work with such a great team at Casmu!

🤝 Nueva Alianza Casmu - Philadelphia International Medicine 🩺🌎 La importancia de este tipo de intercambios es nutritivo para ambos países, no solamente pe...

11/18/2021

“Medical education, research, and innovation are ongoing activities at ALYN, bringing considerable benefits not only to our staff but primarily to our patients,” said Dr. Maurit Beeri, Director General of ALYN Hospital. “By partnering with PIM, we can build a valuable health gateway, connecting our medical teams and professionals. We are looking forward to identifying and developing collaborative initiatives, such as physician exchanges, research projects, and more.”

Read more here --> http://ow.ly/w6Vp50GO97s

11/16/2021

A couple of weeks ago Philadelphia International Medicine CEO, Edgar Vesga, visited the Dominican Republic to meet some of the WorldWide Medical team to discuss transplant programs and medical second opinions in Philadelphia.

Philadelphia International Medicine was recently selected as part of the Worldwide Medical VIP Network providers. To learn more visit us at http://ow.ly/rBJ150GP44R


WorldWide Medical

11/12/2021

The new initiative, known as the ALYN-PIM Health Gateway, will focus on sharing medical technology and expertise.

11/08/2021

We are proud to announce our new partnership with Israel’s ALYN Hospital, Pediatric & Adolescent Rehabilitation Center! Through the ALYN- PIM Health Gateway Initiative, we will collaborate on delivering medical education, joint research, and patient care to benefit the medical community internationally. Read more: http://ow.ly/seVB50GIGma

ALYN Hospital Pediatric & Adolescent Rehabilitation Center Friends of ALYN Hospital

11/04/2021

World renowned physician Dr. Ignazio R. Marino will share insights on The New Era of Medical Tourism and Hospitality on November 8th. Registration is open: http://ow.ly/boJW50GCy3q

Ignazio R. Marino, MD, ScD is executive vice president of Jefferson International Innovative Strategic Ventures. He is a trailblazer in transplant medicine who has also held high public office as a senator of the Republic of Italy and mayor of Rome.

Dr. Marino has performed more than 650 transplants and was a member of the surgical team that performed the only baboon-to-human liver xenotransplants in medical history, and he performed the first transplant in Italy on an HIV-positive patient. He has authored more than 700 scientific publications and four scientific books, and has served on the editorial boards of “Transplantation,” “Liver Transplantation,” “Digestive Diseases and Sciences,” and 15 other international scientific journals. He has also published on the religious, bioethical, and humanitarian aspects of medicine, including a monograph on the future of the Italian national healthcare system.

In 2006, he was elected senator of the Republic of Italy and appointed chair of the Standing Health Committee of the Italian Senate and later, chair within the senate of the Investigative Committee on the National Healthcare System. Dr. Marino was elected mayor of Rome in 2013 and served until 2015.

Jefferson Health Temple University Philadelphia International Medicine